Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 2/20 | 0.76 |
| ▸ | CA12 | O43570 | 1/20 | 0.65 |
| ▸ | CA1 | P00915 | 1/20 | 0.65 |
| ▸ | CA2 | P00918 | 1/20 | 0.65 |
| ▸ | CA4 | P22748 | 1/20 | 0.65 |
| ▸ | CA9 | Q16790 | 1/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.64 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.64 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.64 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.64 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.64 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.64 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30213077 | 0.90 | BCHE (0.67) | BCHECA12CA1CA2CA4 | |
| SCHEMBL1719403 | 0.90 | BCHE (0.67) | BCHECA12CA1CA2CA4 | |
| SCHEMBL19532621 | 0.87 | BCHE (1.00) | BCHEKDM4EALDH1A1LMNACYP3A4 | |
| SCHEMBL19532590 | 0.87 | BCHE (0.71) | BCHECA12CA1CA2CA4 | |
| SCHEMBL19532591 | 0.87 | BCHE (1.00) | BCHEKDM4EALDH1A1LMNACYP3A4 | |
| SCHEMBL19532620 | 0.87 | BCHE (0.71) | BCHECA12CA1CA2CA4 | |
| SCHEMBL5031143 | 0.86 | BCHE (0.74) | BCHECA12CA1CA2CA4 | |
| SCHEMBL9073446 | 0.85 | KDM4E (0.64) | BCHECA12CA1CA2CA4 | |
| SCHEMBL7714458 | 0.85 | BCHE (0.61) | BCHECA12CA1CA2CA4 | |
| SCHEMBL31606732 | 0.84 | KDM4E (0.75) | CA12CA1CA2CA4CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10414778-B2 | Methods for treatment of resistant cancer | NEW MEXICO TECH UNIVERSITY RESEARCH PARK CORPORATION (US) | 2019-09-17 | — | — | US | disclosed |
| WO-2017189834-A1 | METHODS FOR TREATMENT OF RESISTANT CANCER | NEW MEXICO TECH RESEARCH FOUNDATION (US) | 2017-11-02 | — | — | WO | disclosed |
| US-20170313720-A1 | METHODS FOR TREATMENT OF RESISTANT CANCER | NEW MEXICO TECH UNIVERSITY RESEARCH PARK CORPORATION | 2017-11-02 | — | — | US | disclosed |
| US-7432228-B2 | Inhibitor against biosynthesis of abscisic acid | RIKEN (JP) | 2008-10-07 | — | — | US | disclosed |
| US-7098365-B2 | Abscisic acid biosynthesis inhibitor | RIKEN (JP) | 2006-08-29 | — | — | US | disclosed |
| US-20060148650-A1 | Inhibitor against biosynthesis of abscisic acid | RIKEN (JP) | 2006-07-06 | — | — | US | disclosed |
| US-20050014651-A1 | Abscisic acid biosynthesis inhibitor | RIKEN (JP) | 2005-01-20 | — | — | US | disclosed |
| EP-1439165-A1 | ABSCISIC ACID BIOSYNTHESIS INHIBITOR | Riken (JP) | 2004-07-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148650-A1 | Inhibitor against biosynthesis of abscisic acid | COASY, BLVRB, ME1 | BCHE 2262/4885CA12 3926/4885CA1 3294/4885 |
| US-20170313720-A1 | METHODS FOR TREATMENT OF RESISTANT CANCER | MKI67, TP53, TOP2A | BCHE 2358/4885CA12 1123/4885CA1 1697/4885 |
| US-20050014651-A1 | Abscisic acid biosynthesis inhibitor | COASY, BLVRB, ME1 | BCHE 2198/4885CA12 3213/4885CA1 2434/4885 |
| US-10414778-B2 | Methods for treatment of resistant cancer | MKI67, TP53, TOP2A | BCHE 2358/4885CA12 1123/4885CA1 1697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.